Impaired autophagy: A link between neurodegenerative and neuropsychiatric diseases

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 9, 2014, Pages 1705-1711

  Polajnar, Mira ^a,b,c   Žerovnik, Eva ^a  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Autophagy; Neurodegenerative diseases; Progressive myoclonus epilepsies; Protein aggregation; Psychiatric diseases

Indexed keywords

MTOR PROTEIN, HUMAN; PROTEASOME; TARGET OF RAPAMYCIN KINASE;

ANIMAL; AUTOPHAGY; DEGENERATIVE DISEASE; HUMAN; MENTAL DISEASE; METABOLISM; PATHOLOGY; PROTEIN DEGRADATION; UBIQUITINATION; WNT SIGNALING PATHWAY;

ANIMALS; AUTOPHAGY; HUMANS; MENTAL DISORDERS; NEURODEGENERATIVE DISEASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; TOR SERINE-THREONINE KINASES; UBIQUITINATION; WNT SIGNALING PATHWAY;

EID: 84908154973     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12349     Document Type: Article

References (86)

1. Irvine GB, El-Agnaf OM, Shankar GM, et al. Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med. 2008; 14: 451-64.
2. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992; 256: 184-5.
3. Lue LF, Kuo YM, Roher AE, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999; 155: 853-62.
4. Rhein V, Song X, Wiesner A, et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci USA. 2009; 106: 20057-62.
5. Stokin GB, Lillo C, Falzone TL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science. 2005; 307: 1282-8.
6. Butterfield DA, Bush AI. Alzheimer's amyloid beta-peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiol Aging. 2004; 25: 563-8.
7. Lashuel HA, Hartley D, Petre BM, et al. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature. 2002; 418: 291.
8. Duan X, Chang JH, Ge S, et al. Disrupted-In-Schizophrenia 1 regulates integration of newly generated neurons in the adult brain. Cell. 2007; 130: 1146-58.
9. Ishizuka K, Kamiya A, Oh EC, et al. DISC1-dependent switch from progenitor proliferation to migration in the developing cortex. Nature. 2011; 473: 92-6.
10. Leliveld SR, Bader V, Hendriks P, et al. Insolubility of disrupted-in-schizophrenia 1 disrupts oligomer-dependent interactions with nuclear distribution element 1 and is associated with sporadic mental disease. J Neurosci. 2008; 28: 3839-45.
11. Leliveld SR, Hendriks P, Michel M, et al. Oligomer assembly of the C-terminal DISC1 domain (640-854) is controlled by self-association motifs and disease-associated polymorphism S704C. Biochemistry. 2009; 48: 7746-55.
12. Atkin T, Kittler J. DISC1 and the aggresome: a disruption to cellular function? Autophagy. 2012; 8: 851-2.
13. Atkin TA, Brandon NJ, Kittler JT. Disrupted in Schizophrenia 1 forms pathological aggresomes that disrupt its function in intracellular transport. Hum Mol Genet. 2012; 21: 2017-28.
14. Korth C. Aggregated proteins in schizophrenia and other chronic mental diseases: DISC1opathies. Prion. 2012; 6: 134-41.
15. Ogawa F, Malavasi EL, Crummie DK, et al. DISC1 complexes with TRAK1 and Miro1 to modulate anterograde axonal mitochondrial trafficking. Hum Mol Genet. 2014; 23: 906-19.
16. Johnson AW, Jaaro-Peled H, Shahani N, et al. Cognitive and motivational deficits together with prefrontal oxidative stress in a mouse model for neuropsychiatric illness. Proc Natl Acad Sci USA. 2013; 110: 12462-7.
17. McCray BA, Taylor JP. The role of autophagy in age-related neurodegeneration. Neurosignals. 2008; 16: 75-84.
18. Mizushima N, Yamamoto A, Matsui M, et al. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell. 2004; 15: 1101-11.
19. Mizushima N, Levine B, Cuervo AM, et al. Autophagy fights disease through cellular self-digestion. Nature. 2008; 451: 1069-75.
20. Hara T, Nakamura K, Matsui M, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006; 441: 885-9.
21. Komatsu M, Waguri S, Chiba T, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006; 441: 880-4.
22. Nedelsky NB, Todd PK, Taylor JP. Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. Biochim Biophys Acta. 2008; 1782: 691-9.
23. Corboy MJ, Thomas PJ, Wigley WC. Aggresome formation. Methods Mol Biol. 2005; 301: 305-27.
24. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 2000; 10: 524-30.
25. Batlevi Y, Martin DN, Pandey UB, et al. Dynein light chain 1 is required for autophagy, protein clearance, and cell death in Drosophila. Proc Natl Acad Sci USA. 2010; 107: 742-7.
26. Cai ZL, Shi JJ, Yang YP, et al. MPP+ impairs autophagic clearance of alpha-synuclein by impairing the activity of dynein. NeuroReport. 2009; 20: 569-73.
27. Ikenaka K, Kawai K, Katsuno M, et al. dnc-1/dynactin 1 knockdown disrupts transport of autophagosomes and induces motor neuron degeneration. PLoS ONE. 2013; 8: e54511.
28. Ambegaokar SS, Jackson GR. The downward spiral of tau and autolysosomes: a new hypothesis in neurodegeneration. Autophagy. 2012; 8: 1144-5.
29. Martinez-Vicente M, Talloczy Z, Wong E, et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat Neurosci. 2010; 13: 567-76.
30. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000; 103: 253-62.
31. Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004; 36: 585-95.
32. Xiong N, Jia M, Chen C, et al. Potential autophagy enhancers attenuate rotenone-induced toxicity in SH-SY5Y. Neuroscience. 2011; 199: 292-302.
33. Majumder S, Richardson A, Strong R, et al. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS ONE. 2011; 6: e25416.
34. Cortes CJ, Qin K, Cook J, et al. Rapamycin delays disease onset and prevents PrP plaque deposition in a mouse model of Gerstmann-Straussler-Scheinker disease. J Neurosci. 2012; 32: 12396-405.
35. Zhang X, Li L, Chen S, et al. Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Autophagy. 2011; 7: 412-25.
36. Sarkar S, Ravikumar B, Floto RA, et al. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ. 2009; 16: 46-56.
37. Kim D, Nguyen MD, Dobbin MM, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 2007; 26: 3169-79.
38. Khan RS, Fonseca-Kelly Z, Callinan C, et al. SIRT1 activating compounds reduce oxidative stress and prevent cell death in neuronal cells. Front Cell Neurosci. 2012; 6: 63.
39. Frozza RL, Bernardi A, Hoppe JB, et al. Neuroprotective effects of resveratrol against abeta administration in rats are improved by lipid-core nanocapsules. Mol Neurobiol. 2013; 47: 1066-80.
40. Morselli E, Maiuri MC, Markaki M, et al. Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. Cell Death Dis. 2010; 1: e10.
41. Wang IF, Guo BS, Liu YC, et al. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc Natl Acad Sci USA. 2012; 109: 15024-9.
42. Velloso NA, Dalmolin GD, Gomes GM, et al. Spermine improves recognition memory deficit in a rodent model of Huntington's disease. Neurobiol Learn Mem. 2009; 92: 574-80.
43. Fernandez-Estevez MA, Casarejos MJ, Lopez Sendon J, et al. Trehalose reverses cell malfunction in fibroblasts from normal and Huntington's disease patients caused by proteosome inhibition. PLoS ONE. 2014; 9: e90202.
44. Zhang X, Chen S, Song L, et al. MTOR-independent, autophagic enhancer trehalose prolongs motor neuron survival and ameliorates the autophagic flux defect in a mouse model of amyotrophic lateral sclerosis. Autophagy. 2014; 10: 588-602.
45. Rodriguez-Navarro JA, Rodriguez L, Casarejos MJ, et al. Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. Neurobiol Dis. 2010; 39: 423-38.
46. Schaeffer V, Lavenir I, Ozcelik S, et al. Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain. 2012; 135: 2169-77.
47. Aguib Y, Heiseke A, Gilch S, et al. Autophagy induction by trehalose counteracts cellular prion infection. Autophagy. 2009; 5: 361-9.
48. Karapetyan YE, Sferrazza GF, Zhou M, et al. Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents. Proc Natl Acad Sci USA. 2013; 110: 7044-9.
49. Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol. 2005; 4: 239-48.
50. Koskenkorva P, Khyuppenen J, Niskanen E, et al. Motor cortex and thalamic atrophy in Unverricht-Lundborg disease: voxel-based morphometric study. Neurology. 2009; 73: 606-11.
51. Polajnar M, Zerovnik E. Impaired autophagy: a link between neurodegenerative diseases and progressive myoclonus epilepsies. Trends Mol Med. 2011; 17: 293-300.
52. Taylor TN, Greene JG, Miller GW. Behavioral phenotyping of mouse models of Parkinson's disease. Behav Brain Res. 2010; 211: 1-10.
53. Filali M, Lalonde R, Rivest S. Anomalies in social behaviors and exploratory activities in an APPswe/PS1 mouse model of Alzheimer's disease. Physiol Behav. 2011; 104: 880-5.
54. Menalled L, El-Khodor BF, Patry M, et al. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol Dis. 2009; 35: 319-36.
55. Gupta S, Kulhara P. What is schizophrenia: a neurodevelopmental or neurodegenerative disorder or a combination of both? A critical analysis Indian J Psychiatry. 2010; 52: 21-7.
56. Goodwin GM, Martinez-Aran A, Glahn DC, et al. Cognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report. Eur Neuropsychopharmacol. 2008; 18: 787-93.
57. Cannon TD, Thompson PM, van Erp TG, et al. Cortex mapping reveals regionally specific patterns of genetic and disease-specific gray-matter deficits in twins discordant for schizophrenia. Proc Natl Acad Sci USA. 2002; 99: 3228-33.
58. Merenlender-Wagner A, Malishkevich A, Shemer Z, et al. Autophagy has a key role in the pathophysiology of schizophrenia. Mol Psychiatry. 2013; doi:10.1038/mp.2013.174.
59. Haack TB, Hogarth P, Kruer MC, et al. Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am J Hum Genet. 2012; 91: 1144-9.
60. Cleary C, Linde JA, Hiscock KM, et al. Antidepressive-like effects of rapamycin in animal models: implications for mTOR inhibition as a new target for treatment of affective disorders. Brain Res Bull. 2008; 76: 469-73.
61. Kara NZ, Toker L, Agam G, et al. Trehalose induced antidepressant-like effects and autophagy enhancement in mice. Psychopharmacology. 2013; 229: 367-75.
62. Sarkar S, Krishna G, Imarisio S, et al. A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet. 2008; 17: 170-8.
63. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2008; 105: 2052-7.
64. Heiseke A, Aguib Y, Riemer C, et al. Lithium induces clearance of protease resistant prion protein in prion-infected cells by induction of autophagy. J Neurochem. 2009; 109: 25-34.
65. Sarkar S, Floto RA, Berger Z, et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol. 2005; 170: 1101-11.
66. Williams RS, Cheng L, Mudge AW, et al. A common mechanism of action for three mood-stabilizing drugs. Nature. 2002; 417: 292-5.
67. Leng Y, Liang MH, Ren M, et al. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci. 2008; 28: 2576-88.
68. Arico S, Petiot A, Bauvy C, et al. The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem. 2001; 276: 35243-6.
69. Gamez J, Salvado M, Martinez de la Ossa A, et al. Lithium for treatment of amyotrophic lateral sclerosis: much ado about nothing. Neurologia. 2013; doi:10.1016/j.nrl.2013.02.001.
70. Shimada K, Motoi Y, Ishiguro K, et al. Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion. Neurobiol Dis. 2012; 46: 101-8.
71. Li L, Zhang S, Zhang X, et al. Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-beta pathology in a mouse model of Alzheimer's disease. Curr Alzheimer Res. 2013; 10: 433-41.
72. Gao C, Cao W, Bao L, et al. Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation. Nat Cell Biol. 2010; 12: 781-90.
73. Choi JD, Ryu M, Ae Park M, et al. FIP200 inhibits beta-catenin-mediated transcription by promoting APC-independent beta-catenin ubiquitination. Oncogene. 2012; 32: 2421-32.
74. Chang HW, Lee YS, Nam HY, et al. Knockdown of beta-catenin controls both apoptotic and autophagic cell death through LKB1/AMPK signaling in head and neck squamous cell carcinoma cell lines. Cell Signal. 2013; 25: 839-47.
75. Inoki K, Ouyang H, Zhu T, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006; 126: 955-68.
76. Mao Y, Ge X, Frank CL, et al. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell. 2009; 136: 1017-31.
77. Kim JY, Duan X, Liu CY, et al. DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212. Neuron. 2009; 63: 761-73.
78. Li X, Bijur GN, Jope RS. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord. 2002; 4: 137-44.
79. Hall AC, Brennan A, Goold RG, et al. Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol Cell Neurosci. 2002; 20: 257-70.
80. Toledo EM, Inestrosa NC. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol Psychiatry. 2010; 15: 272-85, 28.
81. Purro SA, Dickins EM, Salinas PC. The secreted Wnt antagonist Dickkopf-1 is required for amyloid beta-mediated synaptic loss. J Neurosci. 2012; 32: 3492-8.
82. Killick R, Ribe EM, Al-Shawi R, et al. Clusterin regulates beta-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway. Mol Psychiatry. 2014; 19: 88-98.
83. Rawal N, Corti O, Sacchetti P, et al. Parkin protects dopaminergic neurons from excessive Wnt/beta-catenin signaling. Biochem Biophys Res Commun. 2009; 388: 473-8.
84. Sharma J, Mulherkar S, Mukherjee D, et al. Malin regulates Wnt signaling pathway through degradation of dishevelled2. J Biol Chem. 2012; 287: 6830-9.
85. Carreira-Barbosa F, Concha ML, Takeuchi M, et al. Prickle 1 regulates cell movements during gastrulation and neuronal migration in zebrafish. Development. 2003; 130: 4037-46.
86. Chan DW, Chan CY, Yam JW, et al. Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer. Gastroenterology. 2006; 131: 1218-27.